Sponsored Investor & Scientific Presentation • Informational Overview
Biotechnology & Oncology Research

Turning Cancer’s Defense Into a Vulnerability: Inside MAIA Biotechnology (NYSE: MAIA)

Watch how telomere-targeting research is being studied in oncology. An educational overview of cellular biology and corporate pipeline developments.

Read Video Presentation Transcript

Presentation Summary: Healthy human cells are regulated by a natural biological clock governed by telomeres—protective nucleotide caps at the ends of chromosomes that shorten with each cell division. Once telomeres reach a critical threshold, healthy cells stop dividing.

In over 85% of human cancers, tumor cells reactivate an enzyme called telomerase, which continuously rebuilds telomeres and enables uncontrolled cellular proliferation. Rather than attempting to slowly block telomerase enzyme activity over extended periods, MAIA Biotechnology is researching a telomere-targeting mechanism designed to utilize telomerase activity itself to alter telomere structure, inducing rapid genomic instability in tumor cells and studying secondary immune system activation.

Inside MAIA’s Telomere Science: The Biology of Cellular Division

Every normal somatic cell in the human body has a built-in limit on replication. At the ends of each chromosome sit repetitive DNA sequences known as telomeres, which protect genetic integrity during cell division. With each cycle, these protective structures shorten until the cell enters senescence and ceases dividing.

Tumor cells bypass this natural safeguard. Across the vast majority of solid tumors, cancer cells reactivate telomerase—an enzyme largely inactive in healthy adult tissues—to continually rebuild telomeres and sustain unchecked division.

Flipping the Mechanism: Telomere-Targeting Research

Historically, oncology researchers sought to inhibit telomerase directly, an approach that often required prolonged administration while waiting for existing telomeres to erode naturally. MAIA Biotechnology, Inc. (NYSE American: MAIA) is investigating an alternative scientific framework:

  • Targeted Structural Modification: Studying small-molecule nucleoside analogs recognized by telomerase-positive cells to rapidly disrupt telomere structure.
  • Selective Biological Focus: Because healthy adult cells generally lack active telomerase, this mechanism is designed to concentrate activity within telomerase-expressing tumor cells.
  • Immune Response Research: Evaluating how rapid telomere uncapping and DNA damage signaling interact with innate and adaptive immune pathways.

Corporate & Pipeline Context

As a publicly traded, clinical-stage biopharmaceutical company focused on targeted immunotherapies for oncology, MAIA Biotechnology continues to advance its research programs in advanced solid tumors. Watch the full presentation above to explore the scientific thesis and corporate overview.

Watch the Full Video Presentation on YouTube View additional corporate updates on YouTube or visit MAIA’s Investor Relations portal.

Privacy Policy

This informational page respects visitor privacy. Standard advertising measurement tools (such as the Microsoft Advertising Universal Event Tracking tag) may use cookies or local storage solely to measure aggregate page engagement and video playback performance.

We do not collect protected health information (PHI) or sell personal visitor data. For inquiries regarding MAIA Biotechnology’s corporate privacy practices, please contact ir@maiabiotech.com or write to MAIA Biotechnology, Inc., 444 West Lake Street, Suite 1700, Chicago, IL 60606.

Terms of Use & Forward-Looking Statements

All content on this page is provided "as is" strictly for general educational and investor-awareness purposes. No representation or warranty is made regarding the completeness or accuracy of third-party commentary.

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding preclinical and clinical development timelines, regulatory pathways, and potential therapeutic benefits. Actual results may differ materially from those projected.